Mar
14
2025
EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia
The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating schizophrenia.